Literature DB >> 10431770

Fatigue and magnetic resonance imaging activity in multiple sclerosis.

C Mainero1, J Faroni, C Gasperini, M Filippi, E Giugni, O Ciccarelli, M Rovaris, S Bastianello, G Comi, C Pozzilli.   

Abstract

Fatigue is a frequent and often severe symptom in multiple sclerosis. Pathogenic mechanisms proposed for fatigue include the release of proinflammatory cytokines, which is thought to have an important effect on changes in the blood-brain barrier (BBB). To investigate whether fatigue is related to BBB disruption we studied 11 relapsing-remitting MS patients participating in a multicenter longitudinal study comparing the sensitivity of monthly enhanced magnetic resonance imaging (MRI) after standard-dose and triple-dose injection of gadolinium-diethylene triaminopentoacetic acid (Gd-DTPA). Serial Gd-enhanced MRI studies were performed in two separate sessions every 4 weeks for 3 months. An expanded version of the Fatigue Severity Scale, including 29 items, was administered 24 h before each MRI examination. No relationship was found between the number and volume of Gd-enhancing lesions and fatigue scores at any monthly examination over the study period. Furthermore changes in MRI activity were not significantly related to changes in fatigue scores. These results were obtained on triple-dose delayed scanning, which is more sensitive than standard-dose scanning in detecting areas of BBB disruption. Our preliminary results thus do not support the hypothesis of a relationship between BBB alterations and fatigue severity in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10431770     DOI: 10.1007/s004150050382

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

Review 1.  Fatigue in multiple sclerosis: definition, pathophysiology and treatment.

Authors:  Lauren B Krupp
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Multiple sclerosis related fatigue.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 3.  The neuropsychology of multiple sclerosis: contributions of neuroimaging research.

Authors:  H A Wishart; L Flashman; A J Saykin
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

4.  Biological outcome measurements for behavioral interventions in multiple sclerosis.

Authors:  Anja Fischer; Christoph Heesen; Stefan M Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

5.  Fatigue and progression of corpus callosum atrophy in multiple sclerosis.

Authors:  Özgür Yaldizli; Stephanie Glassl; Dietrich Sturm; Athina Papadopoulou; Achim Gass; Barbara Tettenborn; Norman Putzki
Journal:  J Neurol       Date:  2011-05-19       Impact factor: 4.849

Review 6.  Fatigue in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

7.  Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

Authors:  G Riccitelli; M A Rocca; C Forn; B Colombo; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

8.  The basal ganglia: a substrate for fatigue in multiple sclerosis.

Authors:  N Téllez; J Alonso; J Río; M Tintoré; C Nos; X Montalban; A Rovira
Journal:  Neuroradiology       Date:  2007-10-23       Impact factor: 2.804

9.  Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures.

Authors:  E M Mowry; A Beheshtian; E Waubant; D S Goodin; B A Cree; P Qualley; R Lincoln; M F George; R Gomez; S L Hauser; D T Okuda; D Pelletier
Journal:  Neurology       Date:  2009-05-19       Impact factor: 9.910

10.  Deep gray matter and fatigue in MS: a T1 relaxation time study.

Authors:  G Niepel; Ch R Tench; P S Morgan; N Evangelou; D P Auer; C S Constantinescu
Journal:  J Neurol       Date:  2006-03-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.